
Cencora
COR · NYSE · Health Care
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $68,5 bn
- Div. yield
- 1,0%
- Year to date
- +3,4%
Ratio score
based on 9 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
6 ✓ · 3 — · 0 ✕ · 1 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 19,7 | 25,1 | 25,1 |
| Forward P/E | 16,8 | — | 16,2 |
| PEG | 2,4 | — | 2,2 |
| P/S | 0,2 | 0,2 | 2,2 |
| EV/EBITDA | 15,1 | 14,9 | 17,3 |
| P/FCF | 10,9 | — | 19,5 |
| P/B | 18,6 | 37,3 | 3,4 |
Industry median — across 33 profitable companies in “Health Care” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 20 analysts
- Buy
- 14
- Hold
- 6
- Sell
- 0
Beat the EPS forecast in 3 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q4 2026 | 4,63 | 4,66 | Up +0,7% |
| Q3 2026 | 4,39 | 4,48 | Up +2,0% |
| Q2 2026 | 4,86 | 4,75 | Down −2,3% |
| Q1 2026 | 4,08 | 4,08 | Up 0,0% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 84,8 bn | 78,4 bn | 85,9 bn | 83,7 bn | 80,7 bn | 75,5 bn | 81,5 bn | 79,1 bn | 74,2 bn | 68,4 bn | 72,3 bn | 68,9 bn |
| EPS | 3,94 | 8,40 | 2,87 | −1,74 | 3,52 | 3,68 | 2,50 | 0,04 | 2,42 | 2,09 | 2,98 | 1,73 |
| Margin | 0,9% | 2,1% | 0,7% | −0,4% | 0,9% | 1,0% | 0,6% | 0,0% | 0,7% | 0,6% | 0,8% | 0,5% |
| FCF | 2,43 bn | 1,17 bn | −2,42 bn | 2,88 bn | −74,0 m | 3,22 bn | −2,82 bn | 818 m | 2,36 bn | −991 m | 811 m | 1,65 bn |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: purchases $2,31 m (2 people), sales $15,4 m.
| Name | Amount | Shares | Price |
|---|---|---|---|
| krikorian lazarus2 Nov 2026 · sale | $326 327 | 986 | $330,96 |
| krikorian lazarus1 Oct 2026 · sale | $298 935 | 986 | $303,18 |
| greenberg lon r16 Sep 2026 · sale | $411 264 | 1 280 | $321,30 |
| krikorian lazarus1 Sep 2026 · sale | $321 080 | 985 | $325,97 |
| campbell elizabeth s24 Aug 2026 · sale | $3,66 m | 11 300 | $324,12 |
| tyler lauren m22 Jun 2026 · open-market purchase | $148 627 | 550 | $270,23 |
| durcan dermot mark18 Jun 2026 · open-market purchase | $1,10 m | 4 000 | $274,19 |
| durcan dermot mark28 May 2026 · open-market purchase | $1,07 m | 4 000 | $266,26 |
| mauch robert p.20 Feb 2026 · sale | $1,35 m | 3 762 | $358,94 |
| mauch robert p.18 Feb 2026 · sale | $479 160 | 1 333 | $359,46 |
| mauch robert p.20 Jan 2026 · sale | $1,81 m | 5 096 | $354,73 |
| campbell elizabeth s19 Dec 2025 · sale | $1,15 m | 3 351 | $342,10 |
| battaglia silvana19 Dec 2025 · sale | $578 565 | 1 677 | $345,00 |
| mauch robert p.18 Dec 2025 · sale | $1,75 m | 5 096 | $343,45 |
| krikorian lazarus17 Dec 2025 · sale | $1,38 m | 4 031 | $343,24 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Health Care
- Exchange
- NYSE
- Country
- US
- IPO date
- 28 May 1996
- Website
- www.cencora.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- date not announced
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
CAHCardinal Health | $283,85 | no score | 35,7 | — | — |
BSXBoston Scientific | $43,69 | 83★★★★★★★★★would consider | 18,4 | +8,9% | 16,6% |
EWEdwards Lifesciences | $107,11 | 56★★★★★★★★would watch | 60,3 | +13,4% | 15,2% |
CICigna | $300,16 | 89★★★★★★★★★★would consider | 13,1 | +6,8% | 2,3% |
BDXBecton Dickinson | $216,47 | 38★★★★★★★would not consider | 51,8 | −2,6% | 4,5% |
Ratio — a score by our methodology, not an investment recommendation.




